CommercialDocumentationMedium impact
06.02.01l, Lyme Disease: Diagnosis and Intravenous (IV) Antibiotic Therapy
Independence Blue Cross·Infectious Disease, Emergency Medicine, Family Medicine +1 more·Medical Policy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes medical necessity criteria and coding guidelines for Lyme disease diagnosis and intravenous antibiotic therapy. The billing team must review updated medical necessity requirements and ensure proper coding application for IV antibiotic administration in Lyme disease treatment effective December 29, 2025.
Action Required
By December 29, 2025: Billing and clinical teams must review policy 06.02.01l for specific medical necessity criteria and coding requirements for Lyme disease IV antibiotic therapy. Update billing system rules and provider encounter documentation templates to reflect new medical necessity criteria. Ensure providers document required clinical findings to support medical necessity before submitting claims. Coordinate with providers to understand which specific CPT/HCPCS codes apply under the new criteria. Without proper documentation of medical necessity, claims for IV antibiotic therapy in Lyme disease cases will be denied.